About ProFibrix
ProFibrix is a company based in Leiden (Netherlands) founded in 2004 was acquired by The Medicines Company in June 2013. ProFibrix has raised $33 million across 4 funding rounds from investors including The Medicines Company, Vesalius Biocapital Partners and Index Ventures. ProFibrix operates in a competitive market with competitors including QBiotics, RevBio, MediWound, Dimension Inx and Ilya Pharma, among others.
- Headquarter Leiden, Netherlands
- SectorsHealthcare
- Website profibrix.com
- Social LinkedIn
- Acquired by The Medicines Company (Jun 2013)
- Total Equity Funding$33M (USD)
in 4 rounds
- Latest Funding Round$10.6M (USD), Series B
Aug 2011
- InvestorsThe Medicines Company
& 4 more
- Acquired byThe Medicines Company
(Jun 2013)
Funding Insights of ProFibrix
ProFibrix has successfully raised a total of $33M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $10.6 million completed in August 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33M
- Total Rounds 4
- Last Round Series B — $10.6M
- First Round $11M
(Mar 2007)
- Investors Count 4
All 4 funding rounds of ProFibrix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2011 | $10.6M | Series B | – | – | |
| May 2011 | – | Series B | – | Vesalius Biocapital Partners, Index Ventures | – |
| Aug 2009 | $11.4M | Series B | – | – | |
| Mar 2007 | $11M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in ProFibrix
ProFibrix has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include The Medicines Company, Vesalius Biocapital Partners and Index Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology startups and entrepreneurs. | – | indexventures.com | - | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Life sciences-focused VC firm investing in Europe and Canada | 2007 | vesaliusbiocapital.com | Strassen, Luxembourg | |
AI, deeptech, and healthcare tech companies are funded by Inkef. | – | inkef.com | Amsterdam, Netherlands | |
Markets and developing drugs in areas of acute cardiovascular care, infectious disease care and perioperative care. | 1996 | themedicinescompany.com | Parsippany Troy Hills, United States |
Investor details for ProFibrix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ProFibrix
4 dated milestones of ProFibrix across 9 years, from founding to its latest funding, stage changes and deals.
- Founded ProFibrix is founded.
- Funding First funding round of $11.0M.
- Funding Latest funding round, Series B, of $10.6M.
- Exit Acquired by The Medicines Company.
Competitors of ProFibrix
ProFibrix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QBiotics, RevBio, MediWound, Dimension Inx and Ilya Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qbiotics.com | 2000 | Brisbane, Australia | $98.07M | – | Small molecules from plant extracts are developed for medical applications. | |
| revbio.com | 2014 | Lowell, United States | $24.42M | – | Synthetic adhesives for bone and dental repair are developed. | |
| mediwound.com | 2001 | Yavne, Israel | $18M | – | Enzymatic therapies for tissue repair and regeneration are developed. | |
| dimensioninx.com | 2017 | Chicago, United States | $15.42M | – | 3D biomaterials are provided for regenerative medicine applications. | |
| ilyapharma.se | 2016 | Uppsala, Sweden | $4.02M | – | Biological drugs for skin and mucosa wound treatment are developed. | |
| walkingfishtx.com | 2019 | San Francisco, United States | $123M | – | Cell-based therapeutics for cancer and immunological disorders are developed. | |
| resolution-tx.com | 2017 | Edinburgh, United Kingdom | $119.88M | 6 | Macrophage cell therapies are developed for inflammatory and liver diseases. | |
| clarisbio.com | 2018 | Jersey, United States | $44.5M | – | Topical formulations for corneal wounds, ulcers, and scars are developed. | |
| tempothera.com | 2014 | San Diego, United States | $20.17M | – | Regenerative biomaterials for wounds are developed using particle technology. |
Detailed competitors of ProFibrix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ProFibrix
Websites that share an audience with ProFibrix (profibrix.com).
Websites whose visitors overlap most with ProFibrix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| prosensa.eu | 100% | – | – | View details |
Latest news on Profibrix
Complete news archive for ProFibrix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ProFibrix
10 companies that operate in the same segment as ProFibrix (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ProFibrix
ProFibrix was founded in 2004 and raised its 1st funding round 3 years after it was founded.
ProFibrix is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
ProFibrix is a funded company, having raised a total of $33M across 4 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Mar 2007.
ProFibrix used its fibrinogen technology to develop and commercialize products for the hemostasis and regenerative medicine markets. Profibrixs lead biologic Fibrocaps is a formulation of fibrinogen and thrombin to aid in hemostasis during surgery. ProFibrix was acquired by The Medicines Company in Aug 2013. Fibrocaps is now known as Raplixa and received FDA approval in April 2015.
ProFibrix's top competitors include Ilya Pharma, RevBio and QBiotics.
ProFibrix has 5 investors. Key investors include The Medicines Company, Vesalius Biocapital Partners, Index Ventures, Gilde Healthcare, and Inkef.
Yes. ProFibrix was acquired by The Medicines Company in June 2013.